ATE202709T1 - Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten - Google Patents

Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten

Info

Publication number
ATE202709T1
ATE202709T1 AT95100661T AT95100661T ATE202709T1 AT E202709 T1 ATE202709 T1 AT E202709T1 AT 95100661 T AT95100661 T AT 95100661T AT 95100661 T AT95100661 T AT 95100661T AT E202709 T1 ATE202709 T1 AT E202709T1
Authority
AT
Austria
Prior art keywords
csf
binding protein
pharmaceutically acceptable
tnf binding
acceptable salt
Prior art date
Application number
AT95100661T
Other languages
English (en)
Inventor
Gottfried Alber
Peter Angehrn
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE202709T1 publication Critical patent/ATE202709T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT95100661T 1994-02-04 1995-01-19 Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten ATE202709T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94810059 1994-02-04

Publications (1)

Publication Number Publication Date
ATE202709T1 true ATE202709T1 (de) 2001-07-15

Family

ID=8218199

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95100661T ATE202709T1 (de) 1994-02-04 1995-01-19 Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten

Country Status (16)

Country Link
US (2) US5776895A (de)
EP (1) EP0668077B1 (de)
JP (1) JP2765807B2 (de)
CN (1) CN1097468C (de)
AT (1) ATE202709T1 (de)
AU (1) AU693833B2 (de)
BR (1) BR9500436A (de)
CA (1) CA2139385C (de)
DE (1) DE69521536T2 (de)
DK (1) DK0668077T3 (de)
ES (1) ES2160643T3 (de)
GR (1) GR3036774T3 (de)
NZ (1) NZ270422A (de)
PT (1) PT668077E (de)
RU (1) RU2139084C1 (de)
ZA (1) ZA95679B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998054201A1 (en) * 1997-05-29 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like protein 8
US6419919B2 (en) * 1997-11-07 2002-07-16 John D. Mountz Method for the augmentation of gene expression
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
AU766826B2 (en) * 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
US20020077276A1 (en) * 1999-04-27 2002-06-20 Fredeking Terry M. Compositions and methods for treating hemorrhagic virus infections and other disorders
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US20050271663A1 (en) * 2001-06-28 2005-12-08 Domantis Limited Compositions and methods for treating inflammatory disorders
EP1572936A2 (de) * 2002-03-05 2005-09-14 Eli Lilly And Company Heterologe g-csf-fusionsproteine
US20080008713A1 (en) * 2002-06-28 2008-01-10 Domantis Limited Single domain antibodies against tnfr1 and methods of use therefor
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
US20060002935A1 (en) * 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
JP4980048B2 (ja) 2003-02-28 2012-07-18 アレス トレーディング ソシエテ アノニム 腫瘍壊死因子結合タンパク質の液体製剤
CA2683801A1 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
CN103694337B (zh) 2008-02-08 2016-03-02 Ambrx公司 经修饰瘦素多肽和其用途
UA118536C2 (uk) * 2008-07-23 2019-02-11 Амбркс, Інк. Модифікований поліпептид бичачого гранулоцитарного колонієстимулювального фактора та його застосування
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
CA3077215A1 (en) * 2017-10-11 2019-04-18 Elanco Us Inc. Porcine g-csf variants and their uses

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
EP0396158A1 (de) * 1985-08-23 1990-11-07 Kirin-Amgen, Inc. Herstellung des die pluripotente Granulozyt-Kolonie stimulierenden Faktors
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US4985241A (en) * 1986-11-21 1991-01-15 Cetus Corporation Therapeutic combination of free-radical scavenger and tumor necrosis factor
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
EP1132471A3 (de) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
JP2864434B2 (ja) * 1991-01-18 1999-03-03 サイナーゲン，インコーポレーテッド 腫瘍壊死因子媒介疾患の治療方法
AU3244693A (en) * 1991-12-17 1993-07-19 Schering Corporation Use of the combination of anti-tumor necrosis factor plus interleukin-6 to treat septic shock
PT639079E (pt) * 1992-04-30 2000-04-28 Amgen Inc Composicao para tratamento de doencas mediadas por interleuquina-1 e factor de necrose tumoral
ATE237353T1 (de) * 1992-05-05 2003-05-15 Aeres Biomedical Ltd Antikörper gegen p-selectin und ihre verwendung

Also Published As

Publication number Publication date
EP0668077A1 (de) 1995-08-23
US5750503A (en) 1998-05-12
NZ270422A (en) 1996-06-25
CA2139385C (en) 2001-12-25
DK0668077T3 (da) 2001-10-08
RU2139084C1 (ru) 1999-10-10
DE69521536D1 (de) 2001-08-09
ZA95679B (en) 1995-08-08
AU693833B2 (en) 1998-07-09
JP2765807B2 (ja) 1998-06-18
CN1097468C (zh) 2003-01-01
PT668077E (pt) 2001-12-28
AU1146295A (en) 1995-08-17
CN1111158A (zh) 1995-11-08
CA2139385A1 (en) 1995-08-05
DE69521536T2 (de) 2002-04-18
EP0668077B1 (de) 2001-07-04
BR9500436A (pt) 1995-10-17
GR3036774T3 (en) 2002-01-31
US5776895A (en) 1998-07-07
RU95101385A (ru) 1996-12-27
ES2160643T3 (es) 2001-11-16
JPH07258300A (ja) 1995-10-09

Similar Documents

Publication Publication Date Title
ATE202709T1 (de) Zusammensetzungen die g-csf und ein tnf- bindungsprotein enthalten
HK1004257A1 (en) Use of droloxifene in the treatment of bone diseases
DE3684409D1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
HUT59313A (en) Process for producing pharmaceutical composition comprising flupirtin as active ingredient and suitable for combatting muscular tensions
ATE185268T1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
BR9813373A (pt) Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, processos para efetuar imunossupressão e para tratar ou reduzir o risco de uma doença das vias aérias obstrutiva reversìvel em um paciente
UA41906C2 (uk) Спосіб лікування неврологічних порушень, викликаних травмами
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
BG101118A (en) Therapeutical compounds
CA2148194A1 (en) Cyclopeptides of the formula i
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
EP0347899A3 (en) Pharmaceutical compositions on egg shell basis and their preparation and use
EP0281070A3 (de) Pharmazeutische Zusammensetzung für die Krebsbehandlung
HK124595A (en) Anthocyanidins for the treatment of ophthalmic diseases
MY104521A (en) Treatment of depression.
IL91152A0 (en) Furylthiazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
CA2097878A1 (en) Therapeutic agent for neutropenia
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
EP0384302A3 (de) Verwendung von Ubenimex zur Hestellung eines Medikaments zur Behandlung des myelodysplastischen Syndroms
IL103499A0 (en) Pharmaceutical compositions for treating anxiety in benzodiazepine withdrawn patients
GEP19971029B (en) Antiviral or antibacterial compound and method of use thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification